-
Mashup Score: 1Dementia risk lower in patients with rheumatoid arthritis treated with biologic DMARDs - 6 day(s) ago
Dementia risk decreases among patients with rheumatoid arthritis treated with biologic disease-modifying antirheumatic drugs, according to a systematic review and meta-analysis published in RMD Open.“Chronic systemic inflammation is believed to be involved in the development of dementia,” Wenhui Xie, PhD, of the department of rheumatology and clinical immunology at Peking University
Source: www.healio.comCategories: General Medicine News, RheumatologyTweet
-
Mashup Score: 5FDA approves updated label for Lupkynis with long-term data, new monitoring guidelines - 7 day(s) ago
The FDA has approved an updated label for Lupkynis, an oral treatment for active lupus nephritis, that includes long-term safety and tolerability data, and eases the requirement for monthly kidney function assessments. The new label for Lupkynis (voclosporin, Aurinia Pharmaceuticals) now accounts for a post-hoc analysis of 3-year data from a double-blind, placebo-controlled extension study,
Source: www.healio.comCategories: General Medicine News, RheumatologyTweet
-
Mashup Score: 1Arthritis Awareness Month: Debunking myths, revealing truths - 7 day(s) ago
The month of May serves as Arthritis Awareness Month, drawing attention to this all-too common, yet misunderstood, condition.Although misconceptions may lead people to discount the impact of arthritis, it is one of the most common health conditions in the United States and a leading cause of disability, according to the CDC. Nearly 59 million adults, or one in four, have physician-diagnosed
Source: www.healio.comCategories: General Medicine News, RheumatologyTweet
-
Mashup Score: 0
A new metric reliably confirms giant cell arteritis in suspected cases by combining a validated clinical scoring tool with ultrasonography, according to data in The Lancet Rheumatology.The prediction tool, called the HAS-GCA score, provides an accurate post-test probability for low-, intermediate- and high-risk patients and could enable “correct and rapid confirmation” of GCA in
Source: www.healio.comCategories: General Medicine News, RheumatologyTweet
-
Mashup Score: 6Nearly half of patients with giant cell arteritis achieve remission with upadacitinib - 9 day(s) ago
Nearly half of patients with giant cell arteritis who received upadacitinib while tapering steroids achieved remission from weeks 12 through 52 in a phase 3 trial, according to a press release from AbbVie.“Based on these results, upadacitinib has the potential to be the first oral treatment option for patients with GCA, a disease with inflammation of the large arteries that primarily
Source: www.healio.comCategories: General Medicine News, RheumatologyTweet
-
Mashup Score: 2Sjögren’s spotlight: Healio Rheumatology ’s latest coverage for Sjögren’s Awareness Month - 9 day(s) ago
Sjögren’s disease is one of the most common autoimmune diseases but one of the least known, so to raise awareness of the condition, April is designated Sjögren’s Awareness Month. Patients often wait a long time for their diagnosis, only to find that treatments successful in other autoimmune diseases will not work for them.
Source: www.healio.comCategories: General Medicine News, RheumatologyTweet
-
Mashup Score: 2Blood test predicts knee osteoarthritis up to 8 years in advance - 12 day(s) ago
A blood test successfully predicted most knee osteoarthritis cases up to 8 years before signs of the disease first appeared on X-ray, according to data published in Science Advances. “This confirms our expectation that very early OA is silent and ‘hiding in plain sight’ due to the fact that cartilage tissue has no nerves and therefore can be degraded early on without giving off
Source: www.healio.comCategories: General Medicine News, RheumatologyTweet
-
Mashup Score: 1
Use of biologics to treat moderate to severe systemic lupus erythematosus increased 45% between 2021 and 2023, according to recent findings from a market analysis conducted by Spherix Global Insights.The analysis additionally found that nearly half of moderate-to-severe patients with SLE are currently on a biologic. Meanwhile, among those not currently on a biologic, 73% are considered a
Source: www.healio.comCategories: General Medicine News, RheumatologyTweet
-
Mashup Score: 0
A biosimilar for golimumab has demonstrated therapeutic equivalence in rheumatoid arthritis, with no clinically meaningful safety differences, according to a press release from the manufacturer. The topline results, announced by Alvotech, stem from a confirmatory clinical study for AVT05, the company’s proposed biosimilar to the TNF alpha inhibitors Simponi and Simponi Aria (golimumab,
Source: www.healio.comCategories: General Medicine News, RheumatologyTweet
-
Mashup Score: 0
This year’s Congress of Clinical Rheumatology-East will celebrate the annual meeting’s 40th anniversary with banquets, record in-person attendance and a host of new presenters. “Forty years is a big milestone for us,” David A. McLain, MD, executive director of the Alabama Society for the Rheumatic Diseases, and symposium director of the Congress of Clinical Rheumatology,
Source: www.healio.comCategories: General Medicine News, RheumatologyTweet
🔍Dementia risk decreases among patients with #RheumatoidArthritis treated with biologic DMARDs, according to a systematic review and meta-analysis out of @PKU1898 Find out more with Healio⬇️ https://t.co/FOKjTT0N5D